The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery.
As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.
Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.
Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent acute coronary
- Subjects with the appropriate genetic background and recently hospitalized for ACS (between 1 and 3 months).
- Male and female subjects age 45 years and over at Visit 1.
- AA genotype variant in the ADCY9 gene.
Detailed eligibility discussed when you contact the study team.
DO YOU SUFFER FROM PAIN ASSOCIATED WITH BONE METASTASES OR MULTIPLE MYELOMA?
If so, you may be eligible to participate in a research study being conducted at Weill Cornell Medical College.
- Men & Women 18 years and older
- Diagnosed with bone metastases or multiple myeloma suffering from bone pain and for whom radiation therapy is not an alternative
- Other criteria to be discussed with your doctor or the research team
This clinical trial is for men and women with high-grade gliomas. Glucose (sugar) is thought to be a contributor to tumor growth.
- Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas.
- Participants must not have recurrent disease, must not have been exposed to bevacizumab, and cannot be taking insulin or other oral hypoglycemic.
- Detailed eligibility reviewed when you contact the study team.
This study is being done to compare two standard treatment regimens for acute myeloid leukemia (AML). The first treatment regimen is called DA-90, which involves standard of care drugs daunorubicin (DNR) and Ara-C, is a standard of care upfront treatment regimen for untreated AML.
- Subjects must have a diagnosis of previously untreated acute myeloid leukemia (either AML de novo, AML secondary to myelodysplastic syndromes, or AML secondary towards used therapies or agents which can induce leukemia)
- Subjects must be at least 18 years old and no greater than 60 years old.
- Subjects must have a clinical condition allowing induction treatment to be performed.
- Subjects must have normal liver and kidney function.
*Detailed eligibility criteria will be reviewed when you contact the study team.
Our randomized trial will compare the safety and efficacy of MRI-guided transperineal (TP) versus transrectal ultrasound guided (TRUS) biopsies performed in the outpatient setting. Currently, both methods are standard of care procedures.
- Open to men 18 years or older with suspicion for prostate cancer based upon an elevated PSA or abnormal digital rectal examination (DRE)
- Men with active urinary tract infection, metastatic prostate cancer, history of colorectal surgery limiting insertion of transrectal probe, evidence of acute or chronic prostatitis, or concern for perineal cellulitis or fistula will be excluded.
Certain types of antibodies in the blood may injure a transplanted kidney. Antibodies are types of proteins in the blood that help fight things that are not a part of your own body, like infections.
- Have human leukocyte antigen (HLA) donor-specific antibody (DSA) identified at the time of diagnosis of AMR.
- Have a first qualifying episode of AMR in the participant's current renal allograft between 72 hours (h) and 12 months after transplant.
- Receive first dose of investigational product after 7 days after the kidney transplant procedure and within 7 days after the qualifying renal allograft biopsy procedure that was positive for AMR.
- Have received pediatric en bloc kidney transplant.
- Have primary Focal Segmental Glomerulosclerosis.
- Have prior or concurrent non-renal solid organ transplant or hematopoietic stem cell transplant (HSCT).
- Have a known neoplastic lesion in the transplanted allograft
- Have any ongoing infection
- Have ongoing treatment for hepatitis C virus (HCV) infection.
- Have had a recent myocardial infarction (MI) within the past 6 months and/or at the time of screening.
- Have a history of: abnormal bleeding, clotting events or disorders.
- Have a history of allergic reaction to CINRYZE or other blood products.
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
- Men age 18 an older
- Documented progressive metastatic castration-resistant prostate cancer
- Adequate organ function
- Detailed eligibility reviewed when you contact the study team
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back.
This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer.